Kindstar, ACD Partner on RNA-based MDx | GenomeWeb

NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.

The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.